Special Considerations for the Elderly

  • George T. GrossbergEmail author


Prescribing psychotropic medication for 85-year-olds is more challenging than in younger adults. Due to age-related changes in hepatic metabolism and renal excretion, older adults may require 1/2 to 1/3 the dose of medications that younger adults may need to see therapeutic benefits. Older adults are also more likely to be on several prescriptions and over-the-counter medications – hence, the risk of drug-drug interactions is greater. Lastly, older adults are more sensitive to common side effects of medications, even at low doses. The American Society of Consultant Pharmacists has adopted the saying that “any symptom in an elderly patient should be considered a drug side-effect until proven otherwise.” They are particularly sensitive to sedating and cognitive-impairing side effects of commonly prescribed agents. It is important for clinicians to be familiar with the Beers Criteria or Beers List of so-called good drugs and bad drugs in the elderly.


Psychotropic medication in the elderly Falls in the elderly and psychotropic medication Drug-drug interactions in the elderly Psycho-pharmacotherapy in the elderly Drug metabolism in the elderly 


  1. 1.
    Desai AK. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med. 2003;19:697–719.CrossRefPubMedGoogle Scholar
  2. 2.
    Desai AK, Grossberg GT. Herbals and botanicals in geriatric psychiatry. Am J Geriatr Psychiatr. 2003;11:498–506.CrossRefGoogle Scholar
  3. 3.
    Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2005;118:251–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Steinman MA, Beizer JL, DuBeau CE, et al. How to use the AGS 2015 beers criteria – a guide for patients, clinicians, health systems, and payors. J Am Geriatr Soc. 2015;63(12):e1–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Schneider LS, Dagermen KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized, placebo-controlled trials. J Am Med Assoc. 2005;294:1934–43.CrossRefGoogle Scholar
  6. 6.
    Mollot, RJ Butler D. Federal requirements and regulatory provisions relevant to dementia care and the use of antipsychotic drugs. Long-Term Care Community Coalition. 2012;1–21.Google Scholar
  7. 7.
    Task Force on Aging Research: Medications and Errors. (2009). Accessed Jan 2017.
  8. 8.
    Miller JJ. Serum levels of psychiatric drugs. Psychiatr Times. 2014;19:49.Google Scholar
  9. 9.
    Davis FA. Accessed Jan 2017.
  10. 10.
    Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Desai AK, Grossberg GT. Psychiatric consultation in long-term care. Baltimore: Johns Hopkins University Press; 2010. p. 302.Google Scholar
  12. 12.
    Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17(1):37–49.CrossRefGoogle Scholar
  13. 13.
    Chakkamparambil B, Chibnall JT, Graypel EA, et al. Development of a brief validated geriatric depression screening tool: the SLU “AM SAD”. Am J Geriatr Psychiatr. 2015;23(8):780–3.CrossRefGoogle Scholar
  14. 14.
    Tariq SH, Tumosa N, Chibnall JT, et al. The St. Louis University Mental Status (SLUMS) examination for detecting mild cognitive impairment and dementia is more sensitive than the Mini-Mental Status Examination (MMSE): a pilot study. Am J Geriatr Psychiatr. 2006;14:900–10.CrossRefGoogle Scholar
  15. 15.
    Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jennings L, Grossberg GT. Antipsychotics continue to have a place in the management of difficult behavior problems in patients with dementia. J Am Med Dir Assoc. 2013;14:447–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497–507.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Musich S, Yan C, Yeh CS. Pharmaceutical cost-saving strategies and their association with medication adherence in a medicare supplement. J Gen Intern Med. 2015;30(8):1208–14.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral NeuroscienceSt. Louis University School of MedicineSt. LouisUSA

Personalised recommendations